Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics and cell products

From: Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells

  Patient 1 Patient 2 Patient 3 Patient 4
Patient characteristics     
Age/sex 44/m 69/m 70/m 65/m
Disease T-NHL AML SPL MM
No. prior regimens 4 1 3 7
Donor sister son daughter son
Best response CR CR CR n.e.
a/c GVHD -/- -/n.e. -/- -/n.e.
Outcome R/5 mo R/2 mo R/8 mo e.d./6 wk
Cell dose (10 6 /kg)     
γδ T cells 2.98 0.99 1.23 3.48
NK cells 18.82 12.85 2.26 1.54
αβ T cells 1.74 1.14 2.06 0.70
CD4+ T cells 0.01 0.03 0.02 0.006
CD8+ T cells 0.04 0.06 0.004 0.02
Total 23.59 15.07 5.57 5.75
KIR-mm + - + +
  1. T-NHL indicates T-cell Non-Hodgkin-Lymphoma; AML, Acute Myeloid Leukaemia; SPL, Secondary Plasma Cell Leukaemia; MM, Multiple Myeloma; a/c GVHD, acute/chronic graft-versus-host disease; R, relapse; n.e., not evaluable; e.d., early death; KIR-mm, KIR ligand incompatibility in the graft-versus-host direction.